LianBio (LIANY) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US53000N1081

Price
0.05 USD
Market cap
5.02 m USD
P/E (2025)
1.02
P/S (2025)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
23.94 %
Return on assets (ROA)
23.93 %

LianBio financials

Fiscal year20242025
Gross profit-801,401.00 USD–
Operating income-38.86 m USD-1.27 m USD
Net income2.48 m USD4.91 m USD
Diluted EPS – continuing operations0.02 USD0.05 USD

Full history since 2019, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About LianBio

LianBio, operates as a biotechnology company in China and other Asian countries. It offers medicines for cardiovascular, oncology, ophthalmology, and inflammatory disease indications. The company develops mavacamten for the treatment of obstructive hypertrophic cardiomyopathy, which is in Phase 3 EXPLORER-CN trial; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease, which is in Phase 3 LIBRA trial; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of FGFR2 gene amplification; and BBP-398 for solid tumors. The company was formerly known as LianBio and changed its name to LianMedical in July 2026. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.